West Pharmaceutical Services, Inc.
WST
$251.38
$0.130.05%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.25% | 4.92% | 2.90% | -1.12% | -1.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.25% | 4.92% | 2.90% | -1.12% | -1.92% |
| Cost of Revenue | 3.98% | 3.78% | 3.56% | 3.04% | 4.12% |
| Gross Profit | 10.57% | 7.05% | 1.70% | -8.15% | -11.64% |
| SG&A Expenses | 16.36% | 6.78% | -0.89% | -5.64% | -5.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 44.44% | -52.63% | 33.33% | -25.00% | -30.77% |
| Total Operating Expenses | 5.91% | 4.15% | 2.75% | 1.52% | 2.50% |
| Operating Income | 7.60% | 7.88% | 3.43% | -10.14% | -15.94% |
| Income Before Tax | 2.52% | 1.98% | -2.54% | -14.83% | -16.14% |
| Income Tax Expenses | 13.12% | 18.92% | 20.84% | 0.09% | -12.10% |
| Earnings from Continuing Operations | 0.20% | -1.58% | -7.09% | -17.85% | -16.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.20% | -1.58% | -7.09% | -17.85% | -16.97% |
| EBIT | 7.60% | 7.88% | 3.43% | -10.14% | -15.94% |
| EBITDA | 8.16% | 8.24% | 4.92% | -6.06% | -11.20% |
| EPS Basic | 1.17% | -0.26% | -5.50% | -16.35% | -15.47% |
| Normalized Basic EPS | 8.65% | 9.17% | 4.29% | -9.31% | -14.66% |
| EPS Diluted | 1.45% | 0.32% | -4.82% | -15.83% | -14.97% |
| Normalized Diluted EPS | 9.05% | 9.60% | 4.78% | -8.89% | -14.24% |
| Average Basic Shares Outstanding | -0.96% | -1.30% | -1.59% | -1.76% | -1.75% |
| Average Diluted Shares Outstanding | -1.32% | -1.69% | -2.04% | -2.20% | -2.22% |
| Dividend Per Share | 4.94% | 5.00% | 5.06% | 5.13% | 5.19% |
| Payout Ratio | 0.03% | 0.05% | 0.11% | 0.26% | 0.25% |